Myeloma drugs tested for home use: could cut hospital stays

NCT ID NCT05972135

Recruiting now Disease control Sponsor: SCRI Development Innovations, LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether two drugs, teclistamab and talquetamab, can be given safely in an outpatient setting for people with multiple myeloma. The study will enroll 100 participants who have already tried other treatments. The main goal is to see how often side effects like cytokine release syndrome (CRS) occur when preventive medicines are used, with the hope of making treatment more convenient.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Teclistamab or Talquetamab (drugs given as shots under the skin)
What this could lead to: If successful, this could allow multiple myeloma patients to receive these powerful drugs safely as outpatients, reducing time in the hospital.
What could go wrong: This is a small, early-phase study (100 people) focused on safety and side effects, not yet on cure. Side effects like cytokine release syndrome (CRS) are still a risk, even with preventive medicines.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytokine release syndrome plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Arizona Oncology Associates
RECRUITING

Tucson, Arizona, 85711, United States
Blue Ridge Cancer Center
RECRUITING

Roanoke, Virginia, 24014, United States
Colorado Blood Cancer Institute
RECRUITING

Denver, Colorado, 80218, United States
Florida Cancer Specialists
WITHDRAWN

Lake Mary, Florida, 32746, United States
Maryland Oncology Hematology
RECRUITING

Columbia, Maryland, 21044, United States
Medical Oncology Hematology Consultants
RECRUITING

Newark, Delaware, 19713, United States
Minnesota Oncology Hematology
RECRUITING

Minneapolis, Minnesota, 55404, United States
Oncology Associates of Oregon
RECRUITING

Eugene, Oregon, 97401, United States
Oncology Hematology Care
RECRUITING

Cincinnati, Ohio, 45242, United States
Rocky Mountain Cancer Center
RECRUITING

Denver, Colorado, 80218, United States
Texas Oncology
RECRUITING

Austin, Texas, 78705, United States
Texas Oncology - Northeast Texas
RECRUITING

Tyler, Texas, 75702, United States
Texas Oncology - San Antonio
RECRUITING

San Antonio, Texas, 78240, United States
TriStar Bone Marrow Transplant
RECRUITING

Nashville, Tennessee, 37203, United States
Vanderbilt- Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37232, United States
Virginia Cancer Specialists
RECRUITING

Fairfax, Virginia, 22031, United States
Virginia Oncology Associates
RECRUITING

Elizabeth City, North Carolina, 27909, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.